Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-dimer Adjusted vs Therapeutic LMWH in COVID-19 Pneumonia
NCT04584580Phase 4Unknown
- Sponsor
- Ain Shams University
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin in COVID-19 pneumonia (2 arms), sponsored by Ain Shams University. Primary endpoints: Mortality and Occurrence of venous and/or arterial thrombosis. Status: unknown.
02
Drugs
enoxaparin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04584580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584580.